Propranolol plus molsidomine vs propranolol alone in the treatment of portal hypertension in patients with cirrhosis

Journal of Hepatology

Volumn 24, Issue 4, 1996, Pages 430-435

  García Pagán, Joan Carles ^b   Escorsell, Angels ^b   Feu, Faust ^b   Bandi, Juan Carlos ^b   Moitinho, Eduardo ^b   Casado, Marta ^b   Bosch, Jaunie ^a   Rodés, Joan ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b NONE

Author keywords

Hepatic hemodynamics; Liver cirrhosis; Portal hypertension; Portal pressure

Indexed keywords

MOLSIDOMINE; PROPRANOLOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEMODYNAMICS; HUMAN; LIVER BLOOD FLOW; LIVER CIRRHOSIS; MALE; ORAL DRUG ADMINISTRATION; PORTAL HYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0343593139     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(96)80163-2     Document Type: Article

References (25)

1. Pagliaro L, D'Amico G, Thorkild I, Sörensen TIA, Lebrec D, Burroughs AK, Morabito A, Tiné F, Pofiti F, Traina M. Prevention of first bleeding in cirrhosis. A metaanalysis of randomized trials of nonsurgical treatment. Ann Intern Med 1992; 117: 59-70.
2. Poynard T, Calès P, Pasta L, Ideo G, Pascal JP, Pagliaro L, Lebrec D, and The Franco-Italian Multicenter Study Group. Beta-adrenergic antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. N Engl J Med 1991; 324: 1532-8.
3. Bosch J, Mastai R, Kravetz D, Bruix J, Gaya J, Rigau J, Rodés J. Effects of propranolol on azygos blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984; 4: 1200-5.
4. Garcia-Tsao G, Grace ND, Groszmann RJ, Conn HO, Bermann MM, Patrick MJC, Morse SS, Alberts JL. Short-term effects of propranolol on portal venous pressure. Hepatology 1986; 6: 101-6.
5. Feu F, Bordas JM, Garcia-Pagan JC, Bosch J, Rodés J. Double-blind investigation of the effects of propranolol and placebo on the pressure of esophageal varices in patients with portal hypertension. Hepatology 1991; 13: 917-922.
6. Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, Alberts J, Rodés J, Fisher R, Bermann M, Rofe S, Patrick M, Lerner E. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990; 99:1401-7.
7. Feu F, Cirera I, Garcia-Pagan JC, Luca A, Escorsell A, Bosch J. Rodés J. Portal pressure response to drug therapy predicts the risk of rebleeding from esophageal varices. J Hepatol 1992; 16 (Suppl 1): P1-79 (Abstract).
8. Garcia-Pagan JC, Navasa M, Bosch J. Bru C, Pizcueta MP, Rodés J. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology 1990; 11: 230-8.
9. Garcia-Pagan JC, Feu F, Bosch J, Rodés J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: a randomized controlled study. Ann Intern Med 1991; 114: 869-73.
10. Takeshita A, Nakamura M, Tajimi T, Matsuguchi H, Kuroiwa A, Tanaka S, Kikuchi Y. Long lasting effect of oral molsidomine on exercise performance: a new antianginal agent. Circulation 1977; 55: 401-7.
11. Vinel JP, Monnin JL, Combis JM, Calés P, Desmorat H, Pascal JP. Hemodynamic evaluation of molsidomine: a vasodilator with antianginal properties in patients with alcoholic cirrhosis. Hepatology 1990; 11: 239-42.
12. Ruiz del Arbol L, Garcia-Pagan JC, Feu F, Pizcueta P, Bosch J, Rodés J. Effects of molsidomine, a long acting venous dilator, on portal hypertension: a hemodynamic study in patients with cirrhosis. J Hepatol 1991; 13: 179-86.
13. Desmorat H, Vinel JP, Lahlou O, Pipy B, Badia P, Cales P, Combis JM, Souqual MC, Pascal JPI. Systemic and splanchnic hemodynamic effects of molsidomine in rats with carbon tetrachloride-induced cirrhosis. Hepatology 1991; 13: 1181-4.
14. Kukovetz WR, Holzmann S. Mechanism of vasodilation by molsidomine. Am Heart J 1985; 109: 637-40.
15. Stewart DJ, Elsner D, Sommer O, Holtz J, Bassenge E. Altered spectrum of nitroglycerin action in long-term treatment: nitroglycerin-specific venous tolerance with maintenance of an arterial vasodepressor potency. Circulation 1986; 74: 573-82.
16. Navasa M, Bosch J, Mastai R, Bruix J, Rodés J. Measurement of hepatic blood flow, hepatic extraction and intrinsic clearance of indocyanine green in patients with cirrhosis, comparison of a non-invasive pharmacokinetic method with measurements using hepatic vein catheterization. Eur J Gastroenterol Hepatol 1991; 3: 305-12.
17. Bosch J, Garcia-Pagan JC, Feu F, Rodés J. Portal Hypertension. Clinical Pathobiology. In: Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafrik DA, eds. The Liver: Biology and Pathobiology. New York: Raven Press, Ltd. 1994; 1343-55.
18. Garcia-Pagan JC, Feu F, Ruiz del Arbol L, Navasa M, Bosch J, Rodés J. Long-term haemodynamic effects of isosorbide-5-mononitrate in patients with cirrhosis and portal hypertension. J Hepatol 1990; 11: 189-95.
19. Grose RD, Plevris JN, Redhead DN, Bouchier IA, Hayes PC. The acute and chronic effects of isosorbide-5-mononitrate on portal hemodynamics in cirrhosis. J Hepatol 1994; 20: 542-7.
20. Vorobioff J, Picabea E, Gamen M, Villavicencio R, Bordato J, Bessone F, Tanno H, Palazzi J, Sarano H, Pazzoli L, Sanchez R, Giordano R. Propranolol compared with propranolol plus isosorbide dinitrate in portal hypertensive patients; long-term hemodynamic and renal effects. Hepatology 1993; 18: 477-84.
21. Pereira O, Garcia-Pagán JC, Feu F, Cirera I, Luca A, Bosch J, Rodés J. Factors influencing the portal pressure response to propranolol administration in patients with cirrhosis. Hepatology 1991; 14: 133A (Abstract).
22. Colman JC, Jennings GL, McLean AJ, Mignot PR, Dudley FJ. Propranolol in decompensated alcoholic cirrhosis. Lancet 1982; ii: 1040-1.
23. Bendtsen F, Henriksen JH, Sörensen TIA. Propranolol and hemodynamic response in cirrhosis. J Hepatol 1991; 13: 144-8.
24. Garcia-Pagán JC, Navasa M, Rivera F, Bosch J, Rodés J. Lymphocyte β-2-adrenoceptors and plasma catecholamines in patients with cirrhosis. Relationship with the hemodynamic response to propranolol. Gastroenterology 1992; 102: 2015-23.
25. Weiser JS, Heaer KH, Oltmanns D, Grewe R, Ostrowski J. Zur Pharmakokinetik von Molsidomin bei eingeschränkter LeberFunktion. Herzmedizin 1986; 9: 41-6.